EPI Awarded $175 Million Federal Supply Schedule (FSS) Contract Supporting Veterans and Service Members Through Proven Neuromodulation Therapies
Electromedical Products International, Inc. (EPI), a leader in non-invasive neuromodulation therapeutics, announced it has been awarded a new five-year, $175 million Federal Supply Schedule (FSS) contract.
FDA Grants Breakthrough Device Designation for Closed-Loop tACS
Pulvinar Neuro, a wholly owned subsidiary of Electromedical Products International, Inc. (EPI), has received FDA Breakthrough Device designation for its Closed-Loop Transcranial Alternating Current Stimulation (tACS) device for the treatment of Major Depressive Disorder.
American Journal of Psychiatry Publishes Trial on Breakthrough Technology
Researchers from the Department of Psychiatry at the University of North Carolina – Chapel Hill, in collaboration with Electromedical Products International, Inc. (EPI), have made a breakthrough in treating depression in just five daily sessions.
Electromedical Products International, Inc. Announces Acquisition of Pulvinar Neuro
Electromedical Products International, Inc. (EPI), the leading medical device engineering and manufacturing company using cranial electrotherapy stimulation (CES) to treat mental health and pain disorders, is pleased to announce its acquisition of Pulvinar Neuro.